Galen Senior Fellow Doug Badger has a new paper out this week, published by The Heritage Foundation, showing how a few states that gained waivers to escape some of Obamacare’s expensive, restrictive mandates are helping to lower health insurance premiums for their residents. In his new paper, “How Health Care Premiums Are Declining in States That Seek Relief from Obamacare’s … [Read more...] about How Health Care Premiums Are Declining in States That Seek Relief from Obamacare’s Mandates
Published on RealClearHealth.com | It wasn’t so long ago that Bernie Sanders (I-VT) comfortably occupied the left flank of health care policy. His Medicare For All bill was sufficiently costly, coercive and utopian to set him apart from the pack. Times have changed. When it comes to drug pricing, Bernie faces unexpected intruders on his left: Republicans. In recent months, … [Read more...] about GOP May Outflank Bernie on Drug Price Controls
The liberal talking point is inaccurate. But there’s a reason it resonates with the public. The 2020 presidential race will pit the Democrats’ “Medicare for All” proposal against the Trump administration’s “Medicare for Less.” At least that’s how the Washington Post and some Democratic political operatives suggest it will play out. According to the Post article, … [Read more...] about ‘Medicare for All’ vs. ‘Medicare for Less’?
Published on RealClearHealth.com | Medicare-for-All enthusiasts gaze wistfully at government-run health care systems abroad and see much to admire. When it comes to drug prices, the Trump administration seems to share that admiration. The Department of Health and Human Services is preparing to launch a massive demonstration program that would link Medicare reimbursement for … [Read more...] about Trump Blames the Wrong Government for High Drug Prices
Report Extract: The Trump Administration has proposed using its demonstration authority under section 1115A of the Social Security Act to test a method of reimbursement for physician-administered drugs based on prices in 14 countries. The proposal is controversial, raising constitutional questions about the agency’s authority to modify Medicare reimbursement absent congressional action, as well … [Read more...] about Examination of International Drug Pricing Policies in Selected Countries Shows Prevalent Government Control over Pricing and Restrictions on Access